Mar 18, 2025 08:57PM
Mar 18, 2025 08:55PM
Apr 26, 2024 08:30AM
Jan 30, 2024 05:49AM
Jan 29, 2024 11:53PM
Nov 8, 2023 07:11PM
Jul 31, 2023 07:42AM HUTCHMED (China) (HCM) Reports 2023 Interim Results; Provides Business Updates
Jul 31, 2023 07:41AM
Jun 16, 2023 06:00AM
Jun 15, 2023 08:00PM
May 25, 2023 07:00PM
May 25, 2023 04:31PM
May 25, 2023 04:30PM
Apr 18, 2023 05:49AM HUTCHMED (China) (HCM) Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Apr 17, 2023 08:00PM
Mar 31, 2023 05:49AM
Mar 30, 2023 08:00PM
Mar 14, 2023 09:30AM
Feb 28, 2023 05:51AM
Feb 28, 2023 03:30AM
Jan 23, 2023 05:46AM HUTCHMED (China) (HCM) Sells License for Fruquintinib Outside China to Takeda (TAK)
Jan 23, 2023 03:00AM
Jan 23, 2023 03:00AM
Dec 19, 2022 05:16AM
Dec 19, 2022 05:00AM
Nov 15, 2022 05:39AM
Nov 14, 2022 07:00PM
Nov 14, 2022 05:49AM HUTCHMED (HCM) Reports Positive Topline Result in Fruquintinib Phase III FRUTIGA Study
Nov 13, 2022 07:00PM
Oct 27, 2022 07:30AM
Aug 8, 2022 05:49AM
Aug 7, 2022 08:00PM
Aug 1, 2022 07:01AM
Aug 1, 2022 07:00AM
Aug 1, 2022 02:00AM HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Jun 1, 2022 05:52AM
Jun 1, 2022 04:33AM
May 15, 2022 07:00PM
May 2, 2022 06:00AM
May 2, 2022 06:00AM
Apr 30, 2022 06:00PM
Mar 3, 2022 07:00AM HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
Mar 1, 2022 05:52AM
Mar 1, 2022 03:30AM
Dec 10, 2021 05:00AM
Dec 5, 2021 07:00PM
Dec 3, 2021 05:22AM
Dec 3, 2021 12:00AM
Sep 20, 2021 08:00PM HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China
Sep 19, 2021 08:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All